Nuvectis Pharma Investor Presentation Deck
Targeting YES1 in Cancers of Squamous Cell Origin
Single agent development strategy
YES1/SRC
"off"
SH3
SH2
PYS30
NOP900
1419
Kinase
V530
SH2
E
YES1/SRC
"on"
P
PY419
Kinase
Created with BioRender.com
NuvectisPharma, Inc.
P-
Tyr
Rassf
YAP/TAZ
P.
Tyr YAP/TAZ
TEAD
хото
P
P
FRMD6
KIBRA
MST1/2 SAV1
LATS1/2 MOB1
FAT
1-4
14-3-3
P
YAP/TAZ
Merlin
P
P-
Ser
(80)
Targets involved in organ size,
stem cell renewal, replication,
and survival:
• ID1
• MYC
abox. FGF1
Degradation
• CTGF • Cyclin D
. AREG
• SMAD
High Nuclear YAP Cells Per Well (%)
Low Nuclear
YAP
-5.0
High Nuclear
YAP
NXP900 - IC50 for YAP1
nuclear localization: 24.3nM
I
-2.5
log(Concentration [M])
25
Genetic alterations in the hippo
pathway (FAT1-4, YAP1, TAZ) are
highly prevalent in cancers of
squamous cell origin and confer
sensitivity to NXP900
YES1 drives tumor growth via
phosphorylation and nuclear
localization of YAP1
Significant unmet medical need
opportunities within the squamous
cancer universe ➜ Regulatory
opportunity
18View entire presentation